BCL2L12 Activators
BCL2L12, or BCL2-like 12, is a member of the BCL-2 protein family known for its critical role in regulating apoptosis, a form of programmed cell death essential for maintaining cellular homeostasis and development. This family includes both pro-apoptotic and anti-apoptotic proteins, and BCL2L12 contributes uniquely to this regulatory process.The BCL-2 family proteins are characterized by the presence of BCL-2 homology (BH) domains. BCL2L12, however, is distinct in its structure as it possesses a noncanonical BH domain, making its mode of action and interaction with other BCL-2 family members somewhat unique. This structural difference indicates a specialized role in apoptosis regulation, possibly divergent from classical BCL-2 proteins.
BCL2L12's expression and function have been studied mainly in the context of cancer. It has been observed that in certain types of cancer, such as glioblastoma, BCL2L12 is overexpressed, and this overexpression is associated with the inhibition of apoptosis. This suggests that BCL2L12 may contribute to the survival of cancer cells and resistance to therapy, highlighting its as a target for cancer.In addition to its role in apoptosis, emerging evidence suggests that BCL2L12 may be involved in other cellular processes, such as cell cycle regulation and response to DNA damage. However, the full spectrum of its biological functions and regulatory mechanisms remains an active area of research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can induce apoptosis and potentially upregulate BCL2L12 as a cellular stress response. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-FU is an antimetabolite used in cancer chemotherapy that induces apoptosis, potentially influencing BCL2L12 expression. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and can induce apoptosis, possibly leading to increased BCL2L12 expression in some cellular contexts. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide, a topoisomerase II inhibitor, induces DNA damage and apoptosis, potentially affecting BCL2L12 expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin causes DNA damage leading to apoptosis; this cellular stress might upregulate BCL2L12 expression. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2, enhancing p53 activity and potentially influencing BCL2L12 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA is a histone deacetylase inhibitor that can alter gene expression, potentially affecting BCL2L12 levels. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a kinase inhibitor, induces apoptosis in certain cancer cells, potentially influencing BCL2L12 expression. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
ABT-737, a Bcl-2 family inhibitor, can induce apoptosis, potentially leading to changes in BCL2L12 expression. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin induces endoplasmic reticulum stress and apoptosis, which may influence BCL2L12 expression. | ||||||